Cramer Rosenthal Mcglynn LLC Sells 607,565 Shares of BioLife Solutions, Inc. $BLFS

Cramer Rosenthal Mcglynn LLC reduced its position in BioLife Solutions, Inc. (NASDAQ:BLFS) by 86.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 96,590 shares of the medical equipment provider’s stock after selling 607,565 shares during the quarter. Cramer Rosenthal Mcglynn LLC’s holdings in BioLife Solutions were worth $2,464,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Hantz Financial Services Inc. lifted its position in shares of BioLife Solutions by 54.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock worth $48,000 after purchasing an additional 659 shares during the period. Ameritas Investment Partners Inc. increased its holdings in shares of BioLife Solutions by 12.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock valued at $83,000 after acquiring an additional 441 shares during the period. PNC Financial Services Group Inc. raised its position in shares of BioLife Solutions by 82.0% in the 3rd quarter. PNC Financial Services Group Inc. now owns 4,425 shares of the medical equipment provider’s stock worth $113,000 after acquiring an additional 1,994 shares in the last quarter. Strs Ohio purchased a new stake in shares of BioLife Solutions during the 1st quarter worth $153,000. Finally, Tower Research Capital LLC TRC boosted its position in BioLife Solutions by 547.9% during the second quarter. Tower Research Capital LLC TRC now owns 7,133 shares of the medical equipment provider’s stock valued at $154,000 after purchasing an additional 6,032 shares in the last quarter. Institutional investors own 93.24% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on BLFS. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a report on Wednesday, January 21st. Wall Street Zen upgraded shares of BioLife Solutions from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Zacks Research raised shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 23rd. UBS Group reaffirmed a “buy” rating on shares of BioLife Solutions in a report on Monday, December 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of BioLife Solutions in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, BioLife Solutions has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Key Headlines Impacting BioLife Solutions

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: Company presentation highlighted growth and a strategic refocus, which may support longer-term revenue and margin improvement if execution follows through. Article Title
• Neutral Sentiment: Short-interest reports in early March show anomalous/zero values and NaN changes (days-to-cover ~0), indicating the data source may be unreliable or not meaningful for current positioning.
• Negative Sentiment: Several executives sold shares on March 3 (CMO, CFO, CTO, EVP and other insiders). Combined sales totaled about 2,218 shares for roughly $46,000 — each sale is a small percentage reduction in insider positions (0.13%–0.27%) but the cluster of concurrent filings can create near-term negative sentiment and extra selling pressure. SEC filing example: Form 4

Insider Activity

In other news, Director Amy Duross sold 2,000 shares of the stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $24.60, for a total value of $49,200.00. Following the transaction, the director directly owned 18,687 shares of the company’s stock, valued at approximately $459,700.20. This represents a 9.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Troy Wichterman sold 990 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $25.59, for a total value of $25,334.10. Following the completion of the transaction, the chief financial officer owned 150,746 shares of the company’s stock, valued at approximately $3,857,590.14. The trade was a 0.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 10,020 shares of company stock worth $241,593. Company insiders own 2.20% of the company’s stock.

BioLife Solutions Trading Down 2.7%

NASDAQ BLFS opened at $20.12 on Friday. BioLife Solutions, Inc. has a 12-month low of $19.10 and a 12-month high of $29.62. The company has a fifty day simple moving average of $23.47 and a two-hundred day simple moving average of $25.10. The stock has a market cap of $971.80 million, a P/E ratio of -182.89 and a beta of 1.90.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.